Abstract:Abstract Introduction Burns can progress in depth over time due excessive inflammation, which hinders wound healing. Mesenchymal stem cells have demonstrated promising outcomes in preclinical studies due to their immunomodulatory, anti-apoptotic and regenerative properties. This clinical trial aimed to evaluate safety and effectiveness of culture-expanded allogeneic adipose-derived mesenchymal stem cells (ASCs) in healing of acute burns. Hypothesis: administering stem cell therapy shortly after the burn injury would: 1) reduce burn-induced inflammation, and 2) enhance wound healing dynamics Methods Study design: single-center, phase I, randomized placebo-controlled, double-blind trial on six adult patients with deep partial-thickness burns, each serving as their own control. Two deep partial-thickness burns of uniform size in each patient were randomized to receive dermally injected ASCs and placebo shortly after the burn injury. The primary outcome was change in wound healing using photodigital planimetric quantification of re-epithelialization on days 5, 10, 14 and 21. Secondary outcomes included: safety by recording adverse events and blood sampling for alloimmunization; change in expression of relevant genes (mRNA) by analyzing biopsies at baseline and day 14; change in blood perfusion by laser Doppler imaging at baseline, intervals of 30 min from 0-120 min, day 5, 10, 14 and 21. Descriptive statistics were employed for wound healing, blood perfusion and safety outcomes. For biopsy analysis, differentially expressed genes (DEG) were identified by paired t-test (patient eliminated as factor, p< 0.05), log2FC ≥ |1.00|). Statistical significance was set to p< 0.05, and the FDR adjusted p-values (q values) reported. Results Deep partial-thickness burns were confirmed histologically. Median time from injury to intervention was 15.1 h (range, 10.1-23.9 h). The primary outcome showed that burns treated with stem cells vs. placebo improved the wound healing dynamics with 1.5 to 5.5-fold on different timepoints in the wound healing process (range, day 10-48). In two patients wound healing was negatively impacted by early infections, not related to the cell product. Good safety was demonstrated with no instances of adverse reactions. Only one patient had developed donor-specific HLA antibodies. The mRNA expression analysis showed that five DEG were significant in their change of expression as a result of ASCs: IL-6 (diff: -0.6018, p=0.0494), ITGA11 (diff: -0.7033, p=0.0161), CXCR2 (diff: -0.8459, p=0.011), HLA-B (diff: -1.3286, p=0.0448) and EIF4EBP1 (diff: -1.3498, p=0.0388) all q=0.70. There were no stem-cell related effects on blood perfusion. Conclusions ASC-therapy for burns was safe and demonstrated potential in improving wound healing dynamics. These results encourage further exploratory and confirmatory trials. Applicability of Research to Practice The future perspective is to develop a novel, off-the-shelf, cell-based therapy for burn patients.

717 Survival Benefit with a Topical Anti-inflammatory with Antimicrobial Properties in Patients with >15%; TBSA Burns

546 Winning the Race Against Pathogens: A Regional Burn Center Experience with a Cleansing Protocol

A Multicenter Clinical Trial of Piperacillin/tazobactam in Burn Infection

Evaluation of Topical Off-The-Shelf Therapies to Improve Prolonged Field Care of Burn-Injured Service Members

Topical Antimicrobials for Burn Wound Infections

A 27-Year Follow-Up for a Patient with 100% Total Body Surface Area Burn.

Local Application of Probiotic Bacteria Prophylaxes against Sepsis and Death Resulting from Burn Wound Infection

Surviving Sepsis after Burn Campaign.

42 Multimodal NRF2 and mTOR-targeted Microparticle-based Therapy Reprograms Systemic and Pulmonary Immune Programming After Combined Injury

Topical application of anti-inflammatory agents on burn wounds and their effect on healing

Subcutaneous Anti-inflammatory Therapies to Prevent Burn Progression in a Swine Model of Contact Burn Injury

47 Successful Prevention of Secondary Burn Progressions Using Topical Tacrolimus and Infliximab Hydrogel

733 Massive Burn Injuries: Characteristics, Treatment Strategies and Outcomes from a Single Institution

Antibacterial Efficacy of a Chitosan-Based Hydrogel Modified With Epsilon-Poly-l-Lysine Against Pseudomonas aeruginosa in a Murine-Infected Burn Wound Model

Retrospective Study from a Single Center on the Efficacy of Pulsed Lavage Following Excision of Burns ≥30% of the Total Body Surface Area in 63 Patients

92 Safety & Efficacy of Adipose-derived Stem Cells in Acute Burns: A Randomized Placebo-Controlled Phase-I Trial(ASCAB)

611 Comparison of Autologous Skin Cell Suspension to Conventional Surgical Treatment in Burn Patients

806 Autologous Skin Cell Suspension Demonstrates Successful Outcomes in the Treatment of Burn and Wound Sites

Application of Lactobacillus gasseri 63 AM supernatant to Pseudomonas aeruginosa-infected wounds prevents sepsis in murine models of thermal injury and dorsal excision.

Steven Johnson Syndrome and Toxic Epidermal Necrolysis in a burn unit: A 15-year experience

A novel, reverse-phase-shifting, thermoreversible foaming hydrogel containing antibiotics for the treatment of thermal burns in a swine model – a pilot study

717 Survival Benefit with a Topical Anti-inflammatory with Antimicrobial Properties in Patients with &gt;15%; TBSA Burns